Arrivent Biopharma Inc
AVBP18.780USD
+0.120+0.64%
收盘 08/04, 16:00（美东）报价延迟15分钟
639.29M总市值
亏损市盈率 TTM
关于 Arrivent Biopharma Inc 公司
ArriVent Biopharma, Inc. 是一家临床阶段的生物制药公司。该公司致力于识别、开发和商业化差异化药物，以满足癌症患者未满足的医疗需求。其主要开发候选药物 Furmonertinib 正在推进一系列新型疗法，例如抗体药物偶联物，通过批准和商业化用于癌症患者，最初重点是实体瘤。Furmonertinib 是一种口服、高度脑渗透性、活性突变选择性 EGFR 抑制剂，针对经典（外显子 19 缺失和 L858R）和罕见 EGFR 突变，包括外显子 20 插入突变，以及 HER2 外显子 20 插入突变。Furmonertinib 是一种研究性、新型、EGFR 突变选择性酪氨酸激酶抑制剂，正在开发用于治疗一组 EGFR 突变的 NSCLC 患者。它还专注于 ARR-002 计划的开发和商业化。
公司简介
公司代码AVBP
公司名称Arrivent Biopharma Inc
上市日期Jan 26, 2024
CEODr. Zhengbin (Bing) Yao, Ph.D.
员工数量52
证券类型Ordinary Share
年结日Jan 26
公司地址18 Campus Blvd.
城市NEWTOWN SQUARE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编19073-3269
电话12407806356
网址https://arrivent.com/
公司代码AVBP
上市日期Jan 26, 2024
CEODr. Zhengbin (Bing) Yao, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Robin Lachapelle
Ms. Robin Lachapelle
Chief Operating Officer
Chief Operating Officer
530.21K
+2.15%
Dr. Stuart Lutzker, M.D., Ph.D.
Dr. Stuart Lutzker, M.D., Ph.D.
Director, President of Research and Development
Director, President of Research and Development
--
--
Mr. James Kastenmayer, J.D., Ph.D.
Mr. James Kastenmayer, J.D., Ph.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Mr. Chris W. Nolet
Mr. Chris W. Nolet
Independent Director
Independent Director
--
--
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Zhengbin (Bing) Yao, Ph.D.
Dr. Zhengbin (Bing) Yao, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Lead Independent Director
Lead Independent Director
--
--
Dr. Merdad V. Parsey, M.D., Ph.D.
Dr. Merdad V. Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Robin Lachapelle
Ms. Robin Lachapelle
Chief Operating Officer
Chief Operating Officer
530.21K
+2.15%
Dr. Stuart Lutzker, M.D., Ph.D.
Dr. Stuart Lutzker, M.D., Ph.D.
Director, President of Research and Development
Director, President of Research and Development
--
--
Mr. James Kastenmayer, J.D., Ph.D.
Mr. James Kastenmayer, J.D., Ph.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Mr. Chris W. Nolet
Mr. Chris W. Nolet
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
HHLR Advisors, Ltd.
12.09%
OrbiMed Advisors, LLC
8.16%
Suvretta Capital Management, LLC
6.30%
Fidelity Management & Research Company LLC
5.60%
INFINITUM ASSET MANAGEMENT, LLC
5.57%
Other
62.28%
持股股东
持股股东
占比
HHLR Advisors, Ltd.
12.09%
OrbiMed Advisors, LLC
8.16%
Suvretta Capital Management, LLC
6.30%
Fidelity Management & Research Company LLC
5.60%
INFINITUM ASSET MANAGEMENT, LLC
5.57%
Other
62.28%
股东类型
持股股东
占比
Investment Advisor
24.89%
Investment Advisor/Hedge Fund
17.77%
Venture Capital
13.65%
Hedge Fund
12.94%
Private Equity
8.16%
Corporation
5.52%
Individual Investor
3.50%
Research Firm
0.61%
Bank and Trust
0.47%
Other
12.49%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
170
32.49M
87.70%
-3.54M
2025Q1
168
36.33M
107.08%
+4.56M
2024Q4
146
35.70M
104.98%
+7.05M
2024Q3
118
33.13M
98.31%
+8.97M
2024Q2
99
30.18M
90.13%
+6.97M
2024Q1
80
30.36M
90.72%
+24.09M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
HHLR Advisors, Ltd.
4.48M
12.09%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
3.03M
8.16%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
2.34M
6.3%
+91.50K
+4.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.08M
5.6%
-22.38K
-1.07%
Mar 31, 2025
INFINITUM ASSET MANAGEMENT, LLC
2.07M
5.57%
--
--
May 01, 2025
Octagon Capital Advisors LP
2.06M
5.55%
--
--
Mar 31, 2025
LAV Fund VI LP
2.05M
5.52%
+2.05M
--
Jan 26, 2024
BlackRock Institutional Trust Company, N.A.
1.95M
5.27%
-8.68K
-0.44%
Mar 31, 2025
Novo Holdings A/S
1.87M
5.05%
+122.14K
+6.98%
Mar 31, 2025
Sofinnova Investments, Inc
1.70M
4.57%
--
--
Apr 21, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
iShares Micro-Cap ETF
0.11%
SPDR S&P Biotech ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.83%
iShares Micro-Cap ETF
占比0.11%
SPDR S&P Biotech ETF
占比0.09%
ProShares Ultra Nasdaq Biotechnology
占比0.08%
Invesco Nasdaq Biotechnology ETF
占比0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
占比0.05%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.05%
Vanguard US Momentum Factor ETF
占比0.04%
iShares Biotechnology ETF
占比0.04%
iShares Russell 2000 Growth ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
